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Previous studies showed that exposure of C3H10T12 stem cells to
bonemorphogenetic protein-4 (BMP-4) produced cells that convert
into adipocytes at high frequency when treated with differentia-
tion inducers. In the present investigation, an independent ap-
proach shows that BMP-4 is required for stable commitment of
pluripotent stem cells to the adipocyte lineage. Exposure of pro-
liferating 10T12 stem cells to 5-azacytidine, a potent DNA meth-
ylation inhibitor, gave rise to a subpopulation of cells that can be
cloned and that have the capacity to undergo conversion into
adipocytes upon treatment with terminal differentiation inducers.
Detailed studies performed with a cloned committed subline, the
A33 line, verified stable adipocyte lineage determination in the
absence of exogenous BMP-4. Remarkably, this cell line expresses
and secretes BMP-4 during proliferation in the same time window
that exogenous BMP-4 must be added to naı¨ve 10T12 cells to
induce maximal adipocyte commitment. Furthermore, exposure of
A33 cells to noggin, a naturally occurring BMP-4–binding antag-
onist, during this critical time window blocks subsequent differ-
entiation. The role of BMP-4 in adipocyte lineage commitment is
further strengthened by gene expression profiling of proliferating
10T12 stem cells and A33 preadipocytes. These findings revealed
changes in themolecular circuitry, specifically coordinated changes
in the expression ofmembers of the BMP-4 signaling pathway, that
distinguish A33 preadipocytes from uncommitted parental 10T12
stem cells. Together, these studies provide compelling evidence for
the participation of BMP-4 in adipocyte lineage determination.
5-azacytidine  adipogenesis  determination  mesenchymal stem cell 
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Obesity results from increases in both fat cell size and number(1, 2). During enlargement of adipose tissue depots, adi-
pocytes develop from preadipocytes that are recruited from
pluripotent mesenchymal stem cells (MSCs) in the vascular
stroma of the tissue. MSCs also have the potential to develop into
other mesodermal cell types, including myoblasts, chondroblasts,
and osteoblasts. An understanding of the mechanisms that
govern stem cell lineage determination should aid efforts to
direct or prevent the development of stem cells into specific cell
types for therapeutic uses.
The development of mesenchymal stem cells into terminally
differentiated adipocytes can be divided into four stages: lineage
commitment, preadipocyte proliferation, growth arrest, and
terminal differentiation. Adipose lineage commitment results
from a combinatorial signal that recruits stem cells to become
preadipocytes. In this process, asymmetric cell division occurs, in
which one daughter cell becomes a lineage-restricted preadipo-
cyte, whereas the other daughter cell remains pluripotent to
perpetuate the stem cell population. Proliferation of committed
preadipocytes amplifies the preadipocyte population until space
constraints result in growth arrest. Finally, terminal differenti-
ation of growth-arrested preadipocytes into mature adipocytes is
induced by a second combinatorial signal, and mitotic clonal
expansion further amplifies the population of incipient adipo-
cytes. Thus, commitment of a single stem cell can ultimately
result in the production of large numbers of mature adipocytes.
Further, angiogenesis and neurogenesis are coordinated with
adipogenesis to provide a blood supply and innervation to allow
communication with the central nervous system.
Although 3T3 preadipocyte cell lines (notably the 3T3-L1 and
3T3-F442A lines) have provided an excellent model cell system
with which to elucidate the terminal adipocyte differentiation
program (3–9), a more primitive cell line should be useful in
unraveling earlier steps in adipocyte development. The
C3H10T12 stem cell line derived from C3H mouse embryos (3)
has characteristics that suit it well for studies on the stem cell
commitment program. When dividing 10T12 cells are exposed
to 5-azacytidine (5-azaC), a potent DNA methylation inhibitor,
they undergo commitment to new cell phenotypes, specifically
chondrocytes, myocytes, and adipocytes (10). Blocking DNA
methylation with 5-azaC is thought to induce stable expression
of one or a few genes responsible for lineage commitment
(10–12). Several lines of evidence support this hypothesis (12).
By transfecting cDNA from 5-azaC-committed myoblasts or
preadipocytes into uncommitted stem cells, it was shown that
myocyte (13) or adipocyte (14) commitment could be induced.
Indeed, the first transcription factor shown to be crucial for
myoblast lineage determination, i.e., MyoD, was identified in
such a genetic screen using 10T12 cells and myoblasts (13).
Although analogous preadipocyte cell lines have been isolated
after 5-azaC treatment of 10T12 cells (11, 15), to date no
analogous ‘‘preadipocyte commitment genes’’ have been
identified.
Bone morphogenetic proteins (BMPs) are members of the
TGF- superfamily. Previously, administration of exogenous
BMP-4 to 10T12 cells was shown to induce commitment to the
adipocyte lineage (16, 17). Specifically, when 10T12 cells were
treated with recombinant BMP-4 during proliferation and upon
reaching confluence, subsequent treatment with differentiation
inducers resulted in terminal adipocyte differentiation (17).
Although levels of 50 or 100 ngml BMP-4 resulted in the
differentiation of virtually all 10T12 cells into adipocytes, a
lower level of BMP-4 (10 ngml) was completely ineffective (17).
Thus, a threshold of BMP-4 must be surmounted to induce
adipocyte lineage commitment of 10T12 cells.
During dorsoventral patterning in both invertebrates and
vertebrates, a gradient of BMP-4 signaling encodes positional
information. This morphogen gradient is established in the
extracellular space through the combined actions of several
secreted proteins. Both noggin and chordin bind to BMP-4 with
high affinities and prevent BMP-4 from binding to its cognate
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cell surface receptors. However, the inhibition of BMP signaling
by chordin, but not noggin, can be reversed by xolloidtolloid
proteases. Further, twisted gastrulation (twsg) can have a neg-
ative or a positive effect on BMP signaling. Initially, twsg
promotes the formation of inactive BMP-4–chordin–twsg ter-
nary complexes. However, in the presence of twsg, chordin
becomes a better substrate for BMP-1 (tolloid homologue), and
as a result, twsg positively affects BMP signaling by promoting
the degradation of an inhibitor (18). Thus, BMP-1 functions as
a molecular switch that converts inactive BMP complexes into
active complexes (19). Although BMP-4 was shown to induce
adipocyte commitment of pluripotent stem cells, the other
extracellular components of the BMP-4 network have not pre-
viously been examined in the context of adipogenesis, several of
which are investigated in this paper.
In the present study, 10T12 cells and a committed preadi-
pocyte cell line, the A33 line, derived from 10T12 cells after
5-azaC treatment were used to further elucidate the role of
BMP-4 in the commitment of pluripotent 10T12 stem cells to
the adipocyte lineage. Here we show that proliferating A33 cells
express BMP-4 mRNA and secrete BMP-4, whereas parental
10T12 cells express little BMP-4 during proliferation. This
finding is remarkable, given that A33 cells had not previously
been exposed to exogenous BMP-4.
Results and Discussion
Derivation of the Lineage-Committed A33 Cell Line from 10T12 Stem
Cells. To investigate the genetic events underlying adipocyte
commitment, 10T12 stem cells were treated with 5-azaC at
lowcloning density, and foci were selected for their ability to
produce adipocytes when treated with differentiation inducers.
Of the clonal lines of preadipocytes generated, the A33 line
exhibited the greatest propensity to differentiate into adipocytes
and was further characterized. In the experiments described
below, preadipocyte characteristics of A33 cells were compared
to those of the parental 10T12 cells.
To verify that A33 cells are bona fide preadipocytes, A33 and
10T12 stem cells were plated at low density, allowed to prolif-
erate until confluentgrowth arrested, and then induced to
differentiate using our standard differentiation protocol (20, 21).
Staining with Oil red O 7 days later revealed that A33 cells had
accumulated cytoplasmic fat, whereas the parental 10T12 stem
cells had not (Fig. 1A). Immunoblotting of cell extracts prepared
6 days after exposure to differentiation inducers showed that
markers of terminal adipocyte differentiation, i.e., peroxisome
proliferator-activated receptor (PPAR) and 422aP2, were
expressed by A33 but not by 10T12 cells (Fig. 1B). Further, A33
but not 10T12 cells underwent mitotic clonal expansion, an
established prerequisite for adipogenesis (7), exhibiting an 2-
fold increase in cell number after induction of differentiation
(Fig. 1C).
Additional evidence that A33 cells are preadipocyte deriva-
tives of 10T12 cells was provided by quantitative real-time PCR
(qPCR) analysis of the adipocyte marker PPAR2 (Table 1).
Although PPAR is known to be expressed by terminally
differentiated adipocytes, it is also expressed, albeit at a very low
level by A33 but not 10T12 cells before induction of terminal
differentiation. After induction of differentiation, however, A33
cells express a much higher level of PPAR2 mRNA. The low
level of expression of PPAR2 mRNA by 10T12 cells appears
to reflect the low level (1%) of spontaneous differentiation
that normally occurs with parental 10T12 cells treated with
differentiation inducers. Thus, the expression of PPAR by A33
preadipocytes is initially low, but increases dramatically upon
induction of differentiation. In contrast, uncommitted 10T12
stem cells, neither differentiate (Fig. 1 A–C) nor express signif-
icant levels of PPAR, even when treated with differentiation
inducers (Table 1 and Fig. 1C).
The expression pattern of Pref-1, a preadipocyte marker (22),
was also assessed during commitment and differentiation. Rep-
licate dishes of 10T12 stem cells and A33 cells were plated at
low density, allowed to proliferate and on day 7 (2 days after
reaching confluence), and treated with differentiation inducers.
As illustrated in Table 1, 10T12 stem cells, which lack the
capacity to differentiate, express Pref-1 mRNA whether induced
to differentiate or not. In contrast, committed A33 initially
express Pref-1, but upon entry of the terminal differentiation
program, Pref-1 mRNA levels are markedly reduced. Together,
these findings demonstrate that A33 cells are determined prea-
dipocytes, whereas 10T12 stem cells are not.
Committed A33 Preadipocytes Express BMP-4 During Proliferation.
Because a single gene encoding MyoD activated by 5-azaC was
sufficient to commit 10T12 stem cells to the muscle lineage
(13), we speculated that a single gene (or perhaps a few genes)
in A33 cells might have been responsible for commitment to the
adipocyte lineage. The time window during which we attempted
to identify differentially expressed mRNAs with commitment
potential was the period of rapid cell division preceding growth
Fig. 1. Adipocyte characteristics of A33 cells. (A) Oil red O staining of
cytoplasmic triacylglycerols in 10T12 and A33 cells 7 days after addition of
differentiation inducers. (B) Immunoblotting of the adipocytemarkers PPAR
and 422aP2 from whole-cell extracts of 10T12 and A33 cells 6 days after
induction. (C) Cell number of 10T12 and A33 cells before and 3 days after
induction.
Table 1. PPAR2 and Pref-1 mRNA by qPCR in 10T12 and
A33 cells
Day Inducers
PPAR2 mRNA Pref-1 mRNA
10T12 A33 10T12 A33
3  0 0 0 1  0.1
5  0 0.19  0.02 2  0.2 20  4.1
7  0 0.21  0.03 36  1.3 22  0.8
10  0.76  0.6 66  4.7 23  3.8 2  0.03
Cells were plated such that confluence was reached on day 5, and differ-
entiation inducerswere added on day 7. Values are arbitrary units normalized
to 18S rRNA (mean  SD).








arrest. Because growth arrest is required for the induction of
terminal differentiation (23), it seemed likely that the expression
of adipocyte commitment genes had already occurred by this
point in the development program. Initially therefore, 10T12
stem cells were plated at low density, and mRNA was analyzed
72 h later, long before growth arrest at confluence was achieved.
Because BMP-4 was known to induce adipocyte lineage com-
mitment in 10T12 cells (17), qPCR was initially performed 72 h
after plating to compare mRNA levels of this gene in 10T12
cells and in the A33 preadipocyte subline. At this point, cell
density is 15% of the total number of cells at confluence.
Although initial cell density and growth time were identical by
3 days after plating, the number of A33 cells per dish was 35%
greater than that of 10T12 cells, indicating a higher growth rate
for A33 cells. Remarkably, qPCR indicated a 10-fold increase
in BMP-4 mRNA in A33 cells compared with 10T12 cells at this
time in the program (Fig. 2A). This increase in BMP-4 mRNA
is reflected in increased BMP-4 protein, as demonstrated by
immunoblotting of whole cell extracts prepared at this time (Fig.
2B). Little free BMP-4 was detected in the culture medium
(results not shown), but when the intact A33 cells were treated
with trypsin before lysis, the BMP-4 protein was digested,
demonstrating that virtually all of the BMP-4 present in the
whole-cell extracts is extracellular, as would be expected for
secreted BMP-4. Thus, most if not all of the BMP-4 was
cell-associated, i.e., bound to the cell surface or extracellular
matrix, as reported (24). In addition, an antibody that recognizes
Smads -1, -5, and -8 shows that the levels of these BMP
transducers are increased (Fig. 2B). Moreover, an antibody
specific to the active phosphorylated forms of these Smads
indicates increased BMP-4 activity in proliferating A33 cells
(Fig. 2B).
Next, to assess the timing of BMP-4 expression, BMP-4
mRNA was followed for 7 days after plating at low density, and
confluence was reached after 5 days. As shown in Fig. 2C,
actively proliferating A33 cells express high levels of BMP-4
mRNA, reaching a maximum 3 days after plating and then
declining as growth arrest at confluence occurs. Although both
cell lines are growth-arrestedconfluent by day 5, their patterns
of BMP-4 per cell expression are markedly different. During
active proliferation, 10T12 cells express an extremely low level
of BMP-4 mRNA, which is dramatically up-regulated at growth
arrestconfluence. These findings correlate well with our pre-
vious observation (17) with naı¨ve 10T12 cells that exogenous
BMP-4 must be administered during proliferation and growth
arrest to achieve maximal adipocyte determination. Taken to-
gether, the present findings suggest that BMP-4 provides a signal
for adipocyte determination in A33 cells. To more firmly estab-
lish the importance of BMP-4 in adipocyte commitment, addi-
tional functional tests described below were performed.
Disruption of BMP-4 Signaling by Noggin Blocks the Preadipocyte
Phenotype Exhibited by A33 Cells. To verify that the expression of
BMP-4 by proliferating A33 cells is required for commitment,
the BMP-4-binding protein, noggin, was used to interrupt sig-
naling. Noggin is known to antagonize BMP-4 action by binding
BMP-4 with high affinity and preventing it from binding to its
cognate receptors. A33 cells were plated in replicate and were
treated with recombinant murine noggin 2 and 4 days after
plating. The 2-day time point precedes the spike in BMP-4
mRNA expression that occurs in proliferating A33 cells on day
3 after plating (Fig. 2C). Treatment with noggin throughout
proliferation and postconfluence completely blocked subse-
quent terminal adipocyte differentiation after exposure to dif-
ferentiation inducers, as indicated by a lack of cytoplasmic
triacylglycerol accumulation and PPAR2 expression (Fig. 3).
Fig. 2. Expression of BMP-4 mRNA and protein during proliferation of
10T12 and A33 cells. (A) Real-time PCR determination of BMP-4 mRNA
expression from total RNA prepared from 10T12 and A33 cells 3 days after
plating 22,000 cells per 6-cm dish. (B) BMP-4 protein expression in whole-cell
extracts from 10T12 and A-33 cells treated or not with trypsin and corre-
sponding to day 3 in A. (C) Time course of expression of BMP-4 mRNA by
10T12 and A33 cells after plating as in A.
Fig. 3. Effectof theBMP-4antagonist nogginon theacquisitionofadipocyte
characteristics by A33 cells. One day after plating replicate dishes (22,000 cells
per 6-cm dish) of A33 cells, cells were exposed or not to recombinant mouse
noggin 0–100 ngml. Noggin treatment was continued until postconfluent
dishes were treated with differentiation inducers; photomicrographs were
taken after 4 days and RNA harvested after 6 days. (A and B) Photomicro-
graphs of incipient adipocytes in untreated control A33 cells (A) or A33 cells
treated with 100 ngml noggin (B). (C) Effect of noggin on the expression of
PPAR2 mRNA.
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Further, progressively smaller doses of noggin were progressively
less efficacious, as evidenced by a stepwise decline in PPAR2
mRNA, a marker of terminal adipocyte differentiation (Fig. 3C).
These results provide functional evidence that BMP-4 signaling
is required for the acquisition of the preadipocyte phenotype by
A33 cells.
Importantly, the specificity of noggin for BMP-4 in this
experiment was illustrated by adding 100 ngml rBMP-4 to A33
cells that were exposed to 100 ngml noggin. Because BMP-4 and
noggin have similar molecular masses (13 kDa), these concen-
trations produced an 1:1 molar ratio. Under such conditions,
exogenous BMP-4 completely reversed the inhibitory effect of
noggin (data not shown). These findings demonstrate that
BMP-4 is required for A33 cells to exhibit their determined
preadipocyte phenotype.
Switch in Promoter Usage During Commitment of 10T12 Stem Cells
to A33 Preadipocytes. The murine BMP-4 gene is reported to have
at least two promoters that are differentially regulated during
development (25, 26). Fig. 4A shows a map of the BMP-4 locus
that identifies promoter 1A and 1B and the locations of primer
sets for RT-PCRs to distinguish transcripts produced by these
promoters. RNA from committed A33 cells and 10T12 stem
cells was isolated on day 3 after plating at the point of maximal
BMP-4 expression (Fig. 2C) and on day 7 after both cell types
had undergone growth arrest at confluence. Semiquantitative
RT-PCR of RNA from day 3 cells was analyzed by using primer
set 1AF-3R and showed that promoter 1A is used to drive
expression of BMP-4 in A33 cells, but not 10T12 cells (Fig. 4 B
and C). On day 7, use of promoter 1A and expression of BMP-4
cease. In contrast, RT-PCR of BMP-4 mRNA from uncommit-
ted 10T12 cells with primer set 3BF-3R showed that promoter
1B was used exclusively to drive expression of the BMP-4 gene
at both time points (Fig. 4 B and C). These results suggest that
commitment to the adipocyte lineage induced by 5-azaC may
have altered the methylation status of the BMP-4 gene, render-
ing promoter 1A more accessible for transcriptional activation.
Preliminary findings in our laboratory indicate that a region of
the BMP-4 locus, rich in CpG islands, has fewer methylated Cs
in genomic DNA from A33 cells than from 10T12 cells.
Cell Density and BMP-4 Alter Expression of BMP-4 mRNA by A33 Cells.
The expression of BMP-4 mRNA is markedly affected by the
initial plating density of A33 cells. As shown in Fig. 5A, increas-
ing the initial plating density from 20,000 to 40,000 cells per 6-cm
culture dish caused a 2- to 3-fold increase in the expression of
BMP-4 mRNA (normalized to 18S rRNA) by day 3 after plating
(Fig. 5A). Microscopic examination of the cells at this stage of
Fig. 4. Analyses of BMP-4 mRNA transcripts by semiquantitative RT-PCR. (A) Map of BMP-4 showing location of the primers 1AF (specific for promoter 1A) and
1BF (specific for promoter 1B) as well as the reverse primer (3R) for these transcripts. The amplicon from primers 3F and 4R is common to all BMP-4 transcripts.
(B) RT-PCR data show promoter 1A is only used in proliferating A33 cells. (C) Quantification of the data presented in B.
Fig. 5. Effects of cell density and exogenous BMP-4 on BMP-4mRNA expression by A33 cells. (A) Effect of initial plating density (20,000 or 40,000 cells per 6-cm
dish) on BMP-4 mRNA expression. (B) Effect of exogenous BMP-4 (10 or 50 ngml) on BMP-4 mRNA expression by A33 cells.








proliferation revealed many more foci and cell–cell contacts
between with A33 cells than with 10T12 cells at comparable cell
densities. Two possible causal factors could be involved: (i) A
factor(s) secreted by committed A33 preadipocytes could acti-
vate the expression or decrease the turnover of BMP-4 mRNA,
or (ii) increased cell–cell contact at higher cell densities could
affect BMP-4 synthesis or turnover.
The expression of BMP-4 also appears to be affected by the
ambient concentration of BMP-4. It was repeatedly observed
that, after reaching a maximal level at 3 days after plating,
there is a rapid ‘‘fall off’’ in the expression of BMP-4 over the
next several days (Figs. 5A and 2C). Because BMP-4 is secreted
by A33 cells, it was considered that BMP-4 itself may cause this
decline. As shown in Fig. 5B, the addition of BMP-4 to the
culture medium at a level of 10 or 50 ngml caused an 50%
decrease in the expression of BMP-4 mRNA. This finding
suggests that BMP-4 may inhibit its own expression by a negative
autocrine feedback loop.
mRNA Expression Profiling of 10T12 Stem Cells and A33 Preadipo-
cytes Implicates BMP-4 Signaling Pathway Components in Adipocyte
Lineage Commitment. High-throughput mRNA expression pro-
filing with a customized PCR array, as described in Methods,
was used. The gene list focused on those known to be involved
in BMP-24 signaling, but a few other relevant genes were
included (Table 2, which is published as supporting informa-
tion on the PNAS web site). 10T12 and A33 cells were plated
at low density, and total RNA was isolated 3 days later,
corresponding to the spike in BMP-4 mRNA expression by
A33 cells in Figs. 2C and 5B.
Consistent with results presented in Fig. 2, the PCR array data
show BMP-4 was up-regulated 7-fold in A33 compared to
10T12 cells (Table 2). BMP-2 and -7 mRNAs were not detected
in 10T12 or A33 cells (data not shown). Of note, A33 cells
expressed 2-fold more BMPr2 and BMPr1a mRNA than
10T12 cells, whereas 10T12 cells expressed a low level of
BMPr1b that was not detected in A33 cells (Table 2). These
observations are particularly interesting in light of a study
showing the BMPr1a subtype is coupled to adipogenesis,
whereas the BMPr1b subtype is coupled to chondrogenesis (27).
SMADs are well known intracellular signal transducers of the
BMP pathway, and remarkably all four SMADs (SMADs -1, -4,
-5, and -8) that are downstream of BMP receptors are up-
regulated in A33 cells, Smad-8 increasing 9-fold (Table 2). These
findings agree with the immunoblots of Smad-1, -5, and -8 and
the phosphorylated forms of these Smads presented in Fig. 2B.
The transcriptional profile of several known BMP target genes
including inhibitor of DNA-binding (Id) -1, -2, and -3 were
up-regulated in A33 cells, providing further evidence for in-
creased BMP-4 signaling pathway activity in proliferating A33
cells vs. their undetermined progenitors (Table 2). Ids play
important roles in cell fate determination, so their increase in
expression is likely to be an important component of adipocyte
determination in A33 cells. The Msh-like 2 homeobox gene
(Msx2) is a BMP target gene that plays a role in osteoblast
determination, and Msx2 is reported to be a BMP-2 target in
10T12 cells (28, 29). Msx2 is markedly (10-fold) down-
regulated in A33 cells. These changes in BMP targets are likely
to play a role in the determined preadipocyte phenotype exhib-
ited by A33 cells.
Genes classified as ‘‘extracellular modulators’’ exhibited the
most dynamic differential expression patterns. Noggin mRNA
decreases in A33 cells to a level approximately one-third that in
10T12 cells, consistent with its inhibitory effect on adipocyte
differentiation (Fig. 3). Similarly, the BMP-4 antagonist gremlin
is down-regulated in A33 cells (30). In contrast, chordin mRNA
is increased by 8-fold. Because chordin binds BMP-4 and
antagonizes its activity (31), this observation appears counter-
intuitive. It must be recognized, however, that BMP-1 can cleave
and thereby inactivate chordin, and BMP-1 expression is in-
creased 80% in A33 cells. Further, the murine twsg homologue
(twsg1) increases 2-fold. twsg1 promotes BMP-4 signaling in vivo
by forming a BMP-4–chordin–twsg complex, which makes chor-
din a better substrate for BMP-1 (18). Thus, expression of
BMP-1 and twsg1 by A33 cells would be expected to render the
cells insensitive to chordin. Indeed unlike exogenous noggin,
exogenous chordin is unable to block adipogenesis by A33 cells
(data not shown). Although the basis for up-regulation of
chordin by A33 cells is uncertain, it may serve to ensure that any
BMP-4 that escapes the immediate vicinity of BMP-4 expression
is sequestered by chordin and thus affects only cells that express
BMP-1. In this connection, it should be noted that in Drosophila
chordin is required for maximal BMP-4 signaling.
The most differentially expressed genes identified were the
serine peptidase Htra1 that increased 29-fold in A33 cells and
chordin-like 1 (chrdl1) that increased 56-fold. Although there
is biochemical evidence for Htra1 binding to BMP-4, and
overexpression of this protein can antagonize BMP-4 activity
(32), the physiological role of Htra1 is not clear. Htra1 binds to
collagens and may play a role in extracellular matrix remodeling.
Further investigations are necessary to determine the role of
Htra1 in lineage determination. The rat homologue of chrdl1,
neurogenesin-1, is 97% identical at the amino acid level to mouse
Chrdl1 and is implicated in adult neurogenesis (33). This obser-
vation and the fact that BMP-4 is implicated in sympathetic
nervous system development raise the intriguing possibility that
differentiating preadipocytes may recruitattract sympathetic
neurons to innervate them. Additional experiments to address
this hypothesis are underway. Together, these PCR array find-
ings indicate coordinated changes in the BMP pathway in A33
preadipocytes vs. their pluripotent progenitors that shed light on
their preadipocyte phenotype.
Mesenchymal Cell Fate Determination. Mounting evidence indi-
cates mesenchymal lineage determination is regulated by a
network of extracellular signaling factors that ultimately impinge
on the promoters of lineage-specific transcription factors. In
addition, cell–cell and cell–extracellular matrix interactions af-
fect lineage determination. Further, as opposed to simple linear
pathways leading to specific cell types, the different paths of stem
cell differentiation are interconnected. It is the balance of key
signaling molecules that determines the developmental pathway,
and lineage-specific factors often simultaneously promote one
pathway while inhibiting another. Many key components, extra-
cellular and intracellular, of the developmental network that
controls lineage determination have a bipolar nature. For ex-
ample, Wnt 10b promotes myogenesis while inhibiting adipo-
genesis (34), and BMP-4 promotes adipogenesis while inhibiting
myogenesis (35). In addition, PPAR inhibits chondrogenesis
while stimulating adipogenesis, and Msx2 stimulates osteogen-
esis while inhibiting adipogenesis by inhibiting the transcrip-
tional activity of PPAR. These observations illustrate the
interconnected nature of adipogenesis and chondroosteogen-
esis, the understanding of which has important implications for
the treatment of osteoporosis as well as obesity and diabetes. The
present findings of decreased Msx2 expression in A33 preadi-
pocytes and detectable PPAR2 mRNA in these determined
cells complement previous studies and provide leads for further
investigations. These studies provide evidence that BMP-4 sig-
naling is sufficient and necessary to induce adipocyte lineage
determination in a mesenchymal stem cell model. Further,
coordinated changes in BMP pathway components characterize
determined A33 preadipocytes vs. their pluripotent progenitors.
Although the key targets of BMP-4 have not yet been identified,
the A33 cell line provides an excellent model to identify BMP-4
targets involved in adipocyte determination. In addition, regu-
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latory elements of the BMP-4 gene are expected to bind
transcription factors that play more upstream roles in adipocyte
determination. Studies to identify activators of BMP-4 as well as
its targets are needed.
Methods
Cell Culture and Derivation of A33 Cells. A33 and C3H10T12 stem
cells (American Type Culture Collection, Bethesda, MD) were
propagated and differentiated as described (20, 21). Recombi-
nant murine noggin and chordin and recombinant human BMP-4
were from R&D Systems (Minneapolis, MN). The A33 cell line
was isolated essentially by the method of Constantinides et al.
(36), as described by Konieczny and Emerson (11). 10T12 cells
were plated at cloning density (1,000 cells per 6-cm dish) and
treated with 3 M 5-azaC (Sigma, St. Louis, MO) for 24 h.
5-azaC exposure began 24 h after plating as with previous studies
(10, 11, 15, 36). After 20 days, the cells had formed foci, and
at this time they were treated with differentiation inducers. Some
foci had cells that responded as preadipocytes, i.e., rounded up
and began accumulating fat. Cells from these foci were picked
with cloning cylinders and replated. After subcloning of one of
these cell lines two times, the clone of cells named A33 was
isolated. It should be noted that A33 cells maintained the
characteristics of committed preadipocytes through numerous
(20) passages.
RNA Isolation, Semiquantitative RT-PCR, and qPCR. Total RNA and
was isolated and DNase I treated by using the RNeasy mini kit
according to the protocol of the manufacturer (Qiagen, Valen-
cia, CA). All qPCR experiments were conducted with a
Mx3000P Quantitative PCR System (Stratagene, La Jolla, CA),
essentially as described (37). One-step RT-PCR was used for
examining 18S rRNA, BMP-4, PPAR2, and Pref-l mRNA
levels. Primers were as follows: 18S rRNA (5-tggttgatcctgc-
cagta; 3-cgaccaaaggaaccataact), PPAR2 (5-ccagagcatggtgcct-
tcgct; 3-cagcaaccattgggtcagctc), and Pref-1 (ctgtgtcaatggagtctg-
caag; ctacgatctcacagaagttgc). BMP-4 primers were obtained
from SuperArray Bioscience (Frederick, MD). Standard curves
were used to calculate mRNA levels, and values were normalized
to 18S rRNA amounts. Semiquantitative RT-PCR was used to
distinguish among BMP-4 transcripts as described (25). For PCR
array experiments, an RT2 Profiler Custom PCR Array was used
to simultaneously examine the mRNA levels of 89 genes, in-
cluding five ‘‘housekeeping genes’’ in 96-well plates according to
the protocol of the manufacturer (SuperArray Bioscience). Each
reaction included 40 ng of total RNA and the proper negative
controls (no reverse transcription, no template). 10T12 and
A33 cells were plated at low density, and total RNA was isolated
3.3 (10T12) or 3.0 (A33) days later. The 10T12 cells were
allowed to grow slightly longer, so that at the time of RNA
isolation, the cell density was indistinguishable from that of the
more rapidly dividing A33 cells. RNA of both 10T12 and A33
cells was analyzed in triplicate, and data were normalized for
GAPDH levels by the Ct method.
Immunoblotting. Western blots of cells were performed as de-
scribed (38) with antibodies against BMP-4 (39), CEBP (38),
or 422aP2 (38).
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